NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
- State
- Under way
- Phase
- Phase 3
- People
- 1,175 taking part
- Started
- 28 Feb 2023
- Primary completion
- 16 May 2024
- Arms
- 1400 mg Donanemab - Standard Regimen, 1400 mg Donanemab - Dose Skipping, 1400 mg Donanemab - Titration, 1400 mg Donanemab - Maximum Concentration (Cmax), Donanemab Addendum 2 Arm 1
- Results
- Posted on the registry
- 22 Feb 2023: Trial registered
- 28 Feb 2023: Trial started
- 14 Nov 2025: Trial results posted